# FDA Approves Solco Healthcare's Generic Gabapentin The FDA has approved Solco Healthcare US, LLC's abbreviated new drug application for generic gabapentin oral formulation, expanding competition in the established neurological pain management market dominated by Pfizer's Neurontin. The approval is expected to increase price competition and market share fragmentation among generic manufacturers in the multi-billion-dollar gabapentin category used for neuropathic pain and seizure disorders.